Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Bausch Health Companies Inc BHC

Primary Symbol: T.BHC

Healthcare

Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (GI), hepatology, neurology and dermatology, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with... see more

Add To Watchlist

Recent & Breaking News (TSX:BHC)

Bausch Health Commences Cash Tender Offers And Consent Solicitation For Up To $1,250,000,000 Aggregate Purchase Price

PR Newswire February 22, 2019

Bausch Health Companies Inc. Announces Fourth-Quarter And Full-Year 2018 Results And Provides 2019 Guidance

PR Newswire February 20, 2019

Bausch Health Acquires Eton Pharmaceuticals' EM-100 Investigational Eye Drop For The Treatment Of Itchy Eyes Associated With Allergies

PR Newswire February 19, 2019

Bausch Health Provides Update For DUOBRII Filing

PR Newswire February 15, 2019

Bausch + Lomb Receives 510(k) Clearance For Use Of The Tangible® Hydra-PEG® Custom Contact Lens Coating Technology On Several Of Its Boston® Gas Permeable Lens Materials And Zenlens™ Family Of Scleral Lenses

PR Newswire February 13, 2019

Bausch + Lomb Launches SightMatters.com To Help People Living With Age-Related Macular Degeneration Take Control Of Their Condition

PR Newswire February 4, 2019

Bausch Health Companies Announces Participation In Upcoming Investor Conferences

PR Newswire February 1, 2019

Bausch Health Reduces Debt By Additional $100 Million

PR Newswire January 29, 2019

Bausch Health Companies Inc. Will Release Fourth-Quarter And Full-Year 2018 Financial Results On February 20

PR Newswire January 18, 2019

Bausch Health's Canadian business positioned for growth in 2019

Canada NewsWire January 8, 2019

Bausch Health Provides Company Update At The 37th Annual J.P. Morgan Healthcare Conference

PR Newswire January 7, 2019

Bausch + Lomb Announces HEALTH CANADA Approval Of VYZULTA™ (latanoprostene Bunod Ophthalmic Solution, 0.024%) for the Treatment of Glaucoma

Canada NewsWire January 3, 2019

Bausch Health To Present At The 37th Annual J.P. Morgan Healthcare Conference

PR Newswire January 2, 2019

Bausch Health To Reduce Debt By Additional $76 Million, Bringing Total Debt Repayment In Quarter To Approximately $400 Million

PR Newswire December 19, 2018

Bausch Health Enters Into Definitive "Stalking Horse" Agreement To Acquire Substantially All The Assets Of Synergy Pharmaceuticals Inc.

PR Newswire December 12, 2018

Bausch + Lomb Receives 510(K) Clearance From FDA For Bausch + Lomb Ultra® Multifocal For Astigmatism Contact Lenses

PR Newswire December 5, 2018

Bausch Health Announces Redemption Of $200 Million Aggregate Principal Amount Of Its Outstanding 5.625% Senior Notes Due 2021

PR Newswire November 30, 2018

Bausch Health Announces Closing Of Incremental Amendment To Its Existing Credit Agreement And Redemption Of Its 7.500% Senior Notes Due 2021

PR Newswire November 27, 2018

Bausch Health Announces Early Tender Results And Early Settlement Date For Cash Tender Offer And Consent Solicitation For Any And All Of Its 7.500% Senior Notes Due 2021

PR Newswire November 21, 2018

Bausch Health Announces Participation In Upcoming Investor Conferences

PR Newswire November 19, 2018